Literature DB >> 19282834

Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

J X Zou1, D E Rollison, D Boulware, D-T Chen, E M Sloand, L V Pfannes, J J Goronzy, F Bai, J S Painter, S Wei, D Cosgrove, A F List, P K Epling-Burnette.   

Abstract

Response to immunosuppressive therapy (IST) in younger patients with myelodysplastic syndrome (MDS) has been linked to a T-cell-dominant autoimmune process that impairs hematopoiesis. Analysis of the age-adjusted CD4:CD8 ratio in 76 MDS patients compared with 54 healthy controls showed that inadequate CD4+, rather than expansion of CD8+ T cells, was associated with a lower ratio in a group that included both lower and higher risk MDS patients defined by the International Prognostic Scoring System. In younger MDS patients, naive and memory phenotypes defined by CD45RA and CD62L display showed depletion of naive CD4+ and CD8+ T cells, suggesting a possible relationship to IST responsiveness. To determine the correlation between T-cell subset distribution, T-cell turnover and autoimmunity, a cohort of 20 patients were studied before and after IST. The CD4:CD8 ratio correlated inversely with the proliferative T-cell index before treatment in IST-responsive patients, suggesting that proliferation may be linked to accelerated CD4+ T-cell turnover and hematopoietic failure. Our data show seminal findings that both CD4+ and CD8+ T-cell subsets are dysregulated in MDS. Association between these T-cell defects and response to IST suggests that aberrant T-cell homeostasis and chronic activation are critical determinants influencing autoimmune hematopoietic suppression in younger patients.

Entities:  

Mesh:

Year:  2009        PMID: 19282834      PMCID: PMC3252820          DOI: 10.1038/leu.2009.14

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   12.883


  62 in total

1.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  Biologic characteristics of 164 patients with myelodysplastic syndromes.

Authors:  S Reza; S Dar; T Andric; H Qawi; S Mundle; V Shetty; P Venugopal; I Ali; L Lisak; A Raza
Journal:  Leuk Lymphoma       Date:  1999-04

3.  Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.

Authors:  R J Sokol; S Hewitt; D J Booker
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

Review 4.  Autoimmunity during lymphopenia: a two-hit model.

Authors:  Tom Krupica; Terry J Fry; Crystal L Mackall
Journal:  Clin Immunol       Date:  2006-08       Impact factor: 3.969

5.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

Review 6.  Immunosuppressive treatment of acquired aplastic anemia and immune-mediated bone marrow failure syndromes.

Authors:  Neal S Young
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

7.  A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha.

Authors:  Nuno L Alves; Ester M M van Leeuwen; Ester B M Remmerswaal; Nienke Vrisekoop; Kiki Tesselaar; Eddy Roosnek; Ineke J M ten Berge; René A W van Lier
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

Review 8.  Current treatment options: impact of cytogenetics on the course of myelodysplasia.

Authors:  Naomi Galili; Jan Cerny; Azra Raza
Journal:  Curr Treat Options Oncol       Date:  2007-04

9.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

Review 10.  Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system.

Authors:  Tamàs Fülöp; Anis Larbi; Gilles Dupuis; Graham Pawelec
Journal:  Arthritis Res Ther       Date:  2003-10-16       Impact factor: 5.156

View more
  20 in total

1.  Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.

Authors:  Sophie Dimicoli; Elias Jabbour; Gautam Borthakur; Tapan Kadia; Zeev Estrov; Hui Yang; Mary Kelly; Sherry Pierce; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2011-11-10       Impact factor: 10.047

Review 2.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

3.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 4.  Management of lower-risk myelodysplastic syndromes: the art and evidence.

Authors:  Rami S Komrokji; Mikkael A Sekeres; Alan F List
Journal:  Curr Hematol Malig Rep       Date:  2011-06       Impact factor: 3.952

5.  A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

Authors:  Rami S Komrokji; Adam W Mailloux; Dung-Tsa Chen; Mikkael A Sekeres; Ronald Paquette; William J Fulp; Chiharu Sugimori; Jennifer Paleveda-Pena; Jaroslaw P Maciejewski; Alan F List; Pearlie K Epling-Burnette
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

6.  CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Authors:  Michelle K Gleason; Julie A Ross; Erica D Warlick; Troy C Lund; Michael R Verneris; Andres Wiernik; Stephen Spellman; Michael D Haagenson; Alexander J Lenvik; Mark R Litzow; Pearlie K Epling-Burnette; Bruce R Blazar; Louis M Weiner; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

7.  A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Authors:  Amer M Zeidan; Hanna A Knaus; Tara M Robinson; Andrea M H Towlerton; Edus H Warren; Joshua F Zeidner; Amanda L Blackford; Amy S Duffield; David Rizzieri; Mark G Frattini; Yair M Levy; Mark A Schroeder; Anna Ferguson; Katherine E Sheldon; Amy E DeZern; Ivana Gojo; Steven D Gore; Howard Streicher; Leo Luznik; B Douglas Smith
Journal:  Clin Cancer Res       Date:  2018-05-01       Impact factor: 12.531

8.  Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.

Authors:  Fanqi Bai; Alejandro V Villagra; Jianxiang Zou; Jeffrey S Painter; Kirby Connolly; Michelle A Blaskovich; Lubomir Sokol; Said Sebti; Julie Y Djeu; Thomas P Loughran; Sheng Wei; Eduardo Sotomayor; Pearlie Epling-Burnette
Journal:  Cancer Immunol Immunother       Date:  2011-10-09       Impact factor: 6.630

9.  Immune dysregulation in myelodysplastic syndrome.

Authors:  Chiharu Sugimori; Alan F List; Pearlie K Epling-Burnette
Journal:  Hematol Rep       Date:  2010-01-26

10.  Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Authors:  Kristoffer Evebø Sand; Kristin Paulsen Rye; Bård Mannsåker; Oystein Bruserud; Astrid Olsnes Kittang
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.